Entera Bio Ltd. Ordinary Shares (ENTX) Stock
Fundamentals
Latest news
About Entera Bio Ltd. Ordinary Shares
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Ms. Miranda J. Toledano M.B.A. | CEO & Director | 1977 |
| Dr. Hillel Galitzer M.B.A., Ph.D. | Chief Operating Officer | 1978 |
| Dr. Gregory Burshtein Ph.D. | Chief of Research & Development | 1977 |
| Ms. Dana Yaacov-Garbeli CPA | Chief Financial Officer | 1983 |
| Dr. Rachel B. Wagman | Chief Clinical Advisor | — |
| Ms. Cherin Smith | Executive VP & Head of Clinical Operations | — |
| Dr. Constantin Itin Ph.D., R.Ph. | Head of Biopharmaceutics & Bioanalytics | — |
| Ms. Michele McDermott | MD & EVP of Medical Affairs | — |
| Mr. Riccardo Paolo Camisasca M.D. | Chief Medical Officer | — |



